在性大细胞淋巴瘤中对IL-1R通路的分析和治疗向
Zhihui Song1, Wenjun Wu1, Wei Wei1
1Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA.
Blood
|June 20, 2023
概括
研究人员发现,互白素-1R (IL-1R) 途径对于原发性皮肤形大细胞淋巴瘤 (pC ALCL) 的存活至关重要. 针对这种炎症途径,特别是使用像pacritinib这样的JAK抑制剂,显示出治疗pC ALCL的前景.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 无性大细胞淋巴瘤 (ALCL) 是一种具有攻击性成熟的T细胞瘤,其特征是CD30表达和无性细胞学.
- 了解ALCL分子病理学是识别新型治疗漏洞的关键.
研究的目的:
- 为了全面了解ALCL的分子特征,并确定治疗的弱点.
- 为了研究ALCL病变发生过程中互白素-1R (IL-1R) 炎症通路的作用.
主要方法:
- 全基因组的CRISPR图书馆查对形淋巴瘤激酶阳性 (ALK+) 和初级皮肤 (pC) ALK-ALCL进行了查.
- 在ALCL细胞系和异种移植模型中分析IL-1R通路激活,A20突变,JAK-STAT3信号和药物敏感性.
主要成果:
- 意想不到,IL-1R炎症途径支持pC ALK-ALCL的活力,该ALCL由IL-1α以自身分泌方式激活.
- 在PC-ALCL中,A20功能丧失突变促进IL-1R通路过活化.
- IL-1R途径增强了JAK-STAT3信号传递,并增加了特定ALCL亚型中对JAK抑制剂的敏感性. 帕克里提尼布对pC ALK-ALCL表现出强烈的活性.
结论:
- IL-1R通路在PC ALK-ALCL病变发生过程中起着至关重要的作用.
- 针对IL-1R通路和JAK-STAT3信号提供了一个有前途的治疗策略,用于PC ALCL.
相关概念视频
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
01:31The Intrinsic Apoptotic Pathway
6.6K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.6K
01:24T Cell Types and Functions
1.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.1K